PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 9,200 shares, a decrease of 75.7% from the March 31st total of 37,800 shares. Based on an average daily volume of 115,200 shares, the short-interest ratio is presently 0.1 days.
OTCMKTS PURE remained flat at $$0.17 on Friday. 30,595 shares of the company’s stock were exchanged, compared to its average volume of 42,575. PURE Bioscience has a twelve month low of $0.16 and a twelve month high of $0.65. The stock has a 50 day moving average price of $0.19 and a 200-day moving average price of $0.24.
PURE Bioscience (OTCMKTS:PURE – Get Rating) last released its quarterly earnings data on Tuesday, March 15th. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $0.42 million for the quarter. PURE Bioscience had a negative net margin of 130.17% and a negative return on equity of 107.81%.
PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.
- Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.